SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stephanie M. Perez, Li Chen, Daniel J. Lodge, Alterations in dopamine system function across the estrous cycle of the MAM rodent model of schizophrenia, Psychoneuroendocrinology, 2014, 47, 88

    CrossRef

  2. 2
    Daniel J. Minnema, Kim Z. Travis, Charles B. Breckenridge, Nicholas C. Sturgess, Mark Butt, Jeffrey C. Wolf, Dan Zadory, Melissa J. Beck, James M. Mathews, Merrill O. Tisdel, Andrew R. Cook, Philip A. Botham, Lewis L. Smith, Dietary administration of paraquat for 13weeks does not result in a loss of dopaminergic neurons in the substantia nigra of C57BL/6J mice, Regulatory Toxicology and Pharmacology, 2014, 68, 2, 250

    CrossRef

  3. 3
    Jessica I. Lundin, Thanh G.N. Ton, Andrea Z. LaCroix, W.T. Longstreth, Gary M. Franklin, Phillip D. Swanson, Terri Smith-Weller, Brad A. Racette, Harvey Checkoway, Formulations of hormone therapy and risk of Parkinson's disease, Movement Disorders, 2014, 29, 13
  4. 4
    Byron C. Jones, James P. O'Callaghan, Lu Lu, Robert W. Williams, Gelareh Alam, Diane B. Miller, Genetic correlational analysis reveals no association between MPP+ and the severity of striatal dopaminergic damage following MPTP treatment in BXD mouse strains, Neurotoxicology and Teratology, 2014, 45, 91

    CrossRef

  5. 5
    Gianfranco Spalletta, Fabrizio Piras, Carlo Caltagirone, Sabrina Fagioli, Hippocampal multimodal structural changes and subclinical depression in healthy individuals, Journal of Affective Disorders, 2014, 152-154, 105

    CrossRef

  6. 6
    N. Greene, C. F. Lassen, K. Rugbjerg, B. Ritz, Reproductive factors and Parkinson's disease risk in Danish women, European Journal of Neurology, 2014, 21, 9
  7. 7
    Kara M. Smith, Nabila Dahodwala, Sex differences in Parkinson's disease and other movement disorders, Experimental Neurology, 2014, 259, 44

    CrossRef

  8. 8
    Glenda E. Gillies, Ilse S. Pienaar, Shiv Vohra, Zahi Qamhawi, Sex differences in Parkinson’s disease, Frontiers in Neuroendocrinology, 2014, 35, 3, 370

    CrossRef

  9. 9
    R.L. Dennis, D.C. Lay, H.W. Cheng, Effects of early serotonin programming on behavior and central monoamine concentrations in an avian model, Behavioural Brain Research, 2013, 253, 290

    CrossRef

  10. 10
    Rodolfo Savica, Brandon R. Grossardt, James H. Bower, J. Eric Ahlskog, Walter A. Rocca, Risk factors for Parkinson's disease may differ in men and women: an exploratory study, Hormones and Behavior, 2013, 63, 2, 308

    CrossRef

  11. 11
    Paolo Solla, Antonino Cannas, Federica Carla Ibba, Federico Loi, Marta Corona, Gianni Orofino, Maria Giovanna Marrosu, Francesco Marrosu, Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease, Journal of the Neurological Sciences, 2012, 323, 1-2, 33

    CrossRef

  12. 12
    Q. David Walker, Misha L. Johnson, Amanda E.D. Van Swearingen, Andrew E. Arrant, Joseph M. Caster, Cynthia M. Kuhn, Individual differences in psychostimulant responses of female rats are associated with ovarian hormones and dopamine neuroanatomy, Neuropharmacology, 2012, 62, 7, 2267

    CrossRef

  13. 13
    R. Pattarini, Y. Rong, K.R. Shepherd, Y. Jiao, C. Qu, R.J. Smeyne, J.I. Morgan, Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine, Neuroscience, 2012, 214, 84

    CrossRef

  14. 14
    A. Blake Buletko, Dean E. Dluzen, Janet L. McDermott, Altaf S. Darvesh, Werner J. Geldenhuys, Markers associated with testosterone enhancement of methamphetamine-induced striatal dopaminergic neurotoxicity, Neurotoxicology and Teratology, 2012, 34, 3, 338

    CrossRef

  15. 15
    Luke S. Poth, Bryan P. O'connell, Janet L. Mcdermott, Dean E. Dluzen, Nomifensine alters sex differences in striatal dopaminergic function, Synapse, 2012, 66, 8
  16. 16
    S. Al Sweidi, M. G. Sánchez, M. Bourque, M. Morissette, D. Dluzen, T. Di Paolo, Oestrogen Receptors and Signalling Pathways: Implications for Neuroprotective Effects of Sex Steroids in Parkinson’s Disease, Journal of Neuroendocrinology, 2012, 24, 1
  17. 17
    Mélanie Bourque, Dean E. Dluzen, Thérèse Di Paolo, Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson’s disease, Frontiers in Neuroendocrinology, 2012, 33, 2, 169

    CrossRef

  18. You have free access to this content18
    Susan Duty, Peter Jenner, Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease, British Journal of Pharmacology, 2011, 164, 4
  19. 19
    Jennifer L. Madison, Michal Wegrzynowicz, Michael Aschner, Aaron B. Bowman, Gender and manganese exposure interactions on mouse striatal neuron morphology, NeuroToxicology, 2011, 32, 6, 896

    CrossRef

  20. 20
    J. A. Moreno, K. M. Streifel, K. A. Sullivan, W. H. Hanneman, R. B. Tjalkens, Manganese-Induced NF- B Activation and Nitrosative Stress Is Decreased by Estrogen in Juvenile Mice, Toxicological Sciences, 2011, 122, 1, 121

    CrossRef

  21. 21
    Eleni Antzoulatos, Michael W. Jakowec, Giselle M. Petzinger, Ruth I. Wood, MPTP Neurotoxicity and Testosterone Induce Dendritic Remodeling of Striatal Medium Spiny Neurons in the C57Bl/6 Mouse, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  22. 22
    Darcy Litteljohn, Eric Nelson, Cheri Bethune, Shawn Hayley, The effects of paraquat on regional brain neurotransmitter activity, hippocampal BDNF and behavioural function in female mice, Neuroscience Letters, 2011, 502, 3, 186

    CrossRef

  23. 23
    Sun Ju Chung, Sebastian M. Armasu, Joanna M. Biernacka, Timothy G. Lesnick, David N. Rider, Julie M. Cunningham, Demetrius M. Maraganore, Variants in estrogen-related genes and risk of Parkinson's disease, Movement Disorders, 2011, 26, 7
  24. 24
    Rochelle R. Torgerson, Burning mouth syndrome, Dermatologic Therapy, 2010, 23, 3
  25. 25
    Min Hyung Jung, Heung Yeol Kim, Effects of estrogen on cognition and dementia, Journal of Women's Medicine, 2010, 3, 4, 141

    CrossRef

  26. 26
    Glenda E. Gillies, Simon McArthur, Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens, Hormones and Behavior, 2010, 57, 1, 23

    CrossRef

  27. 27
    M. L. Johnson, C. C. Ho, A. E. Day, Q. D. Walker, R. Francis, C. M. Kuhn, Oestrogen Receptors Enhance Dopamine Neurone Survival in Rat Midbrain, Journal of Neuroendocrinology, 2010, 22, 4
  28. 28
    D.E. Dluzen, J.L. McDermott, A.S. Darvesh, Relationships among gender, age, time, and temperature in methamphetamine-induced striatal dopaminergic neurotoxicity, Neuroscience, 2010, 167, 4, 985

    CrossRef

  29. You have free access to this content29
    Maria Gabriela Sánchez, Mélanie Bourque, Marc Morissette, Thérèse Di Paolo, Steroids-Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders, CNS Neuroscience & Therapeutics, 2010, 16, 3
  30. 30
    Ilona Joniec, Agnieszka Ciesielska, Iwona Kurkowska-Jastrzebska, Adam Przybylkowski, Anna Czlonkowska, Andrzej Czlonkowski, Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Brain Research, 2009, 1261, 7

    CrossRef

  31. 31
    Marc Morissette, Thérèse Di Paolo, Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys, Journal of Neuroscience Research, 2009, 87, 7
  32. 32
    Xuan V. Nguyen, Mei Liu, Hyoung-Chun Kim, Guoying Bing, Effects of prodynorphin deletion on striatal dopamine in mice during normal aging and in response to MPTP, Experimental Neurology, 2009, 219, 1, 228

    CrossRef

  33. 33
    Min-juan Bian, Li-mei Li, Mei Yu, Jian Fei, Fang Huang, Elevated interleukin-1β induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice, Brain Research, 2009, 1302, 256

    CrossRef

  34. 34
    Natalie S. Werner, Thomas Meindl, Julia Materne, Rolf R. Engel, Dorothea Huber, Michael Riedel, Maximilian Reiser, Kristina Hennig-Fast, Functional MRI study of memory-related brain regions in patients with depressive disorder, Journal of Affective Disorders, 2009, 119, 1-3, 124

    CrossRef

  35. 35
    Masanori Ookubo, Hironori Yokoyama, Hiroyuki Kato, Tsutomu Araki, Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice, Molecular and Cellular Endocrinology, 2009, 311, 1-2, 62

    CrossRef

  36. 36
    D. Litteljohn, E. Mangano, N. Shukla, S. Hayley, Interferon-γ deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat, Neuroscience, 2009, 164, 4, 1894

    CrossRef

  37. 37
    Mélanie Bourque, Dean E. Dluzen, Thérèse Di Paolo, Neuroprotective actions of sex steroids in Parkinson’s disease, Frontiers in Neuroendocrinology, 2009, 30, 2, 142

    CrossRef

  38. 38
    Kelly Claire Simon, Honglei Chen, Xiang Gao, Michael A. Schwarzschild, Alberto Ascherio, Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease, Movement Disorders, 2009, 24, 9
  39. 39
    Arianna Manciocco, Flavia Chiarotti, Augusto Vitale, Gemma Calamandrei, Giovanni Laviola, Enrico Alleva, The application of Russell and Burch 3R principle in rodent models of neurodegenerative disease: The case of Parkinson’s disease, Neuroscience & Biobehavioral Reviews, 2009, 33, 1, 18

    CrossRef

  40. 40
    Agnieszka Ciesielska, I. Joniec, I. Kurkowska-Jastrzębska, A. Cudna, A. Przybyłkowski, A. Członkowska, A. Członkowski, The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson’s disease, Inflammation Research, 2009, 58, 11, 747

    CrossRef

  41. 41
    Nicole M. Gatto, Myles Cockburn, Jeff Bronstein, Angelika D. Manthripragada, Beate Ritz, Well-Water Consumption and Parkinson’s Disease in Rural California, Environmental Health Perspectives, 2009, 117, 12, 1912

    CrossRef

  42. 42
    A.M. Etgen, L.M. Garcia-Segura, Hormones, Brain and Behavior, 2009,

    CrossRef

  43. 43
    M. Morissette, M. Le Saux, M. D’Astous, S. Jourdain, S. Al Sweidi, N. Morin, E. Estrada-Camarena, Pablo Mendez, Luis Miguel Garcia-Segura, T. Di Paolo, Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain, The Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 3-5, 327

    CrossRef

  44. 44
    D.E. Dluzen, S. Bhatt, J.L. McDermott, Differences in reserpine-induced striatal dopamine output and content between female and male mice: Implications for sex differences in vesicular monoamine transporter 2 function, Neuroscience, 2008, 154, 4, 1488

    CrossRef

  45. 45
    Yuxin Liu, Liya Qin, Belinda Wilson, Xuefei Wu, Li Qian, Ann-Charlotte Granholm, Fulton T. Crews, Jau-Shyong Hong, Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits, NeuroToxicology, 2008, 29, 5, 864

    CrossRef

  46. 46
    Marc Morissette, Sara Al Sweidi, Sophie Callier, Thérèse Di Paolo, Estrogen and SERM neuroprotection in animal models of Parkinson's disease, Molecular and Cellular Endocrinology, 2008, 290, 1-2, 60

    CrossRef

  47. 47
    M.C. Morale, F. L'Episcopo, C. Tirolo, G. Giaquinta, S. Caniglia, N. Testa, P. Arcieri, P.-A. Serra, G. Lupo, M. Alberghina, N. Harada, S. Honda, G.C. Panzica, Bianca Marchetti, Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?, Brain Research Reviews, 2008, 57, 2, 431

    CrossRef

  48. 48
    David M. Thomas, Dina M. Francescutti-Verbeem, Donald M. Kuhn, Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling, Journal of Neurochemistry, 2008, 106, 2
  49. 49
    Jing Ji, Dean E. Dluzen, Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice, Journal of Neural Transmission, 2008, 115, 6, 809

    CrossRef

  50. 50
    Chandani Lewis, Dean E. Dluzen, Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice, Neuroscience Letters, 2008, 448, 1, 130

    CrossRef

  51. 51
    Talene A. Yacoubian, Ippolita Cantuti-Castelvetri, Bérengère Bouzou, Georgios Asteris, Pamela J. McLean, Bradley T. Hyman, David G. Standaert, Transcriptional dysregulation in a transgenic model of Parkinson disease, Neurobiology of Disease, 2008, 29, 3, 515

    CrossRef

  52. 52
    Vernice Jackson-Lewis, Serge Przedborski, Parkinson's Disease, 2008,

    CrossRef

  53. 53
    J.L. McDermott, D.E. Dluzen, Aging and sex differences in striatal dopaminergic function, Neuroscience, 2007, 149, 2, 401

    CrossRef

  54. 54
    Pablo Najt, Mark Nicoletti, Hua Hsuan Chen, John P. Hatch, Sheila C. Caetano, Roberto B. Sassi, David Axelson, Paolo Brambilla, Macheri S. Keshavan, Neal D. Ryan, Boris Birmaher, Jair C. Soares, Anatomical measurements of the orbitofrontal cortex in child and adolescent patients with bipolar disorder, Neuroscience Letters, 2007, 413, 3, 183

    CrossRef

  55. 55
    Ippolita Cantuti-Castelvetri, Christine Keller-McGandy, Bérengère Bouzou, Georgios Asteris, Timothy W. Clark, Matthew P. Frosch, David G. Standaert, Effects of gender on nigral gene expression and parkinson disease, Neurobiology of Disease, 2007, 26, 3, 606

    CrossRef

  56. 56
    Lisa M. Shulman, Gender differences in Parkinson's disease, Gender Medicine, 2007, 4, 1, 8

    CrossRef

  57. 57
    Lauren L. Patton, Michael A. Siegel, Raphael Benoliel, Antoon De Laat, Management of burning mouth syndrome: systematic review and management recommendations, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2007, 103, S39.e1

    CrossRef

  58. 58
    Bin Liu, Dean E Dluzen, OESTROGEN AND NIGROSTRIATAL DOPAMINERGIC NEURODEGENERATION: ANIMAL MODELS AND CLINICAL REPORTS OF PARKINSON'S DISEASE, Clinical and Experimental Pharmacology and Physiology, 2007, 34, 7
  59. 59
    Vernice Jackson-Lewis, Serge Przedborski, Protocol for the MPTP mouse model of Parkinson's disease, Nature Protocols, 2007, 2, 1, 141

    CrossRef

  60. 60
    Marc Morissette, Sandra Jourdain, Sara Al Sweidi, Frank S. Menniti, Andres D. Ramirez, Thérèse Di Paolo, Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity, Neuropharmacology, 2007, 52, 7, 1509

    CrossRef

  61. 61
    J. Ji, J. L. McDermott, D. E. Dluzen, Sex Differences in K+-Evoked Striatal Dopamine Output from Superfused Striatal Tissue Fragments of Reserpine-Treated CD-1 Mice, Journal of Neuroendocrinology, 2007, 19, 9
  62. 62
    Simon McArthur, Hilary E. Murray, Alihusein Dhankot, David T. Dexter, Glenda E. Gillies, Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition, Journal of Neurochemistry, 2007, 100, 3
  63. 63
    Mélanie Bourque, Bin Liu, Dean E. Dluzen, Thérèse Di Paolo, Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity, Biochemical Pharmacology, 2007, 74, 9, 1413

    CrossRef

  64. 64
    Roberta Frigerio, Kevin R. Sanft, Brandon R. Grossardt, Brett J. Peterson, Alexis Elbaz, James H. Bower, J. Eric Ahlskog, Mariza De Andrade, Demetrius M. Maraganore, Walter A. Rocca, Chemical exposures and Parkinson's disease: A population-based case–control study, Movement Disorders, 2006, 21, 10
  65. 65
    Jeffrey M. Brown, Shawn Gouty, Varsha Iyer, John Rosenberger, Brian M. Cox, Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression, Journal of Neurochemistry, 2006, 98, 2
  66. 66
    Bin Liu, Dean E. Dluzen, Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system, Synapse, 2006, 60, 5
  67. 67
    D. Reglödi, A. Lubics, P. Kiss, I. Lengvári, B. Gaszner, G. Tóth, O. Hegyi, A. Tamás, Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats, Neuropeptides, 2006, 40, 4, 265

    CrossRef

  68. 68
    Farida Sohrabji, Danielle K. Lewis, Estrogen–BDNF interactions: Implications for neurodegenerative diseases, Frontiers in Neuroendocrinology, 2006, 27, 4, 404

    CrossRef

  69. 69
    M.C. Morale, P.A. Serra, F. L’Episcopo, C. Tirolo, S. Caniglia, N. Testa, F. Gennuso, G. Giaquinta, G. Rocchitta, M.S. Desole, E. Miele, B. Marchetti, Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: Glia dictates resistance versus vulnerability to neurodegeneration, Neuroscience, 2006, 138, 3, 869

    CrossRef

  70. 70
    Jitka Lindová, Martina Novotná, Jan Havlíček, Eva Jozífková, Anna Skallová, Petra Kolbeková, Zdeněk Hodný, Petr Kodym, Jaroslav Flegr, Gender differences in behavioural changes induced by latent toxoplasmosis, International Journal for Parasitology, 2006, 36, 14, 1485

    CrossRef

  71. 71
    Lisa M Shulman, Viveca Bhat, Gender disparities in Parkinson’s disease, Expert Review of Neurotherapeutics, 2006, 6, 3, 407

    CrossRef

  72. 72
    Vidhya Kunnathur, Kamal Shemisa, Bin Liu, Ty J. Salvaterra, Dean E. Dluzen, Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine, Neurotoxicology and Teratology, 2006, 28, 5, 557

    CrossRef

  73. 73
    Cynthia A. Munro, Mary E. McCaul, Dean F. Wong, Lynn M. Oswald, Yun Zhou, James Brasic, Hiroto Kuwabara, Anil Kumar, Mohab Alexander, Weiguo Ye, Gary S. Wand, Sex Differences in Striatal Dopamine Release in Healthy Adults, Biological Psychiatry, 2006, 59, 10, 966

    CrossRef

  74. 74
    Aristea S. Galanopoulou, Sex- and cell-type-specific patterns of GABAA receptor and estradiol-mediated signaling in the immature rat substantia nigra, European Journal of Neuroscience, 2006, 23, 9
  75. 75
    Kamal Shemisa, Vidhya Kunnathur, Bin Liu, Ty J. Salvaterra, Dean E. Dluzen, Testosterone modulation of striatal dopamine output in orchidectomized mice, Synapse, 2006, 60, 5
  76. 76
    JAMES A. DYKENS, WALTER H. MOOS, NEIL HOWELL, Development of 17α-Estradiol as a Neuroprotective Therapeutic Agent: Rationale and Results from a Phase I Clinical Study, Annals of the New York Academy of Sciences, 2005, 1052, 1
  77. 77
    Deborah A. Cory-Slechta, Mona Thiruchelvam, Brian K. Barlow, Eric K. Richfield, Developmental Pesticide Models of the Parkinson Disease Phenotype, Environmental Health Perspectives, 2005, 113, 9, 1263

    CrossRef

  78. 78
    Sandeep D. Bhatt, Dean E. Dluzen, Dopamine transporter function differences between male and female CD-1 mice, Brain Research, 2005, 1035, 2, 188

    CrossRef

  79. 79
    L.I. Anderson, R.E. Leipheimer, D.E. Dluzen, Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice, Neuroscience, 2005, 130, 2, 369

    CrossRef

  80. 80
    Diana Amantea, Rossella Russo, Giacinto Bagetta, Maria Tiziana Corasaniti, From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens, Pharmacological Research, 2005, 52, 2, 119

    CrossRef

  81. 81
    Y. Baba, J. D. Putzke, N. R. Whaley, Z. K. Wszolek, R. J. Uitti, Gender and the Parkinson’s disease phenotype, Journal of Neurology, 2005, 252, 10, 1201

    CrossRef

  82. 82
    Dean E. Dluzen, Ty J. Salvaterra, Sex Differences in Methamphetamine-Evoked Striatal Dopamine Output Are Abolished following Gonadectomy: Comparisons with Potassium-Evoked Output and Responses in Prepubertal Mice, Neuroendocrinology, 2005, 82, 2, 78

    CrossRef

  83. 83
    Th. Foltynie, S. G. J. Lewis, T. E. Goldberg, A. D. Blackwell, B. S. Kolachana, D. R. Weinberger, T. W. Robbins, R. A. Barker, The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease, Journal of Neurology, 2005, 252, 7, 833

    CrossRef

  84. 84
    Acioly L.T Lacerda, Matcheri S Keshavan, Antonio Y Hardan, Ozgur Yorbik, Paolo Brambilla, Roberto B Sassi, Mark Nicoletti, Alan G Mallinger, Ellen Frank, David J Kupfer, Jair C Soares, Anatomic evaluation of the orbitofrontal cortex in major depressive disorder, Biological Psychiatry, 2004, 55, 4, 353

    CrossRef

  85. 85
    DEAN E. DLUZEN, JANET L. MCDERMOTT, Developmental and Genetic Influences upon Gender Differences in Methamphetamine-Induced Nigrostriatal Dopaminergic Neurotoxicity, Annals of the New York Academy of Sciences, 2004, 1025, 1
  86. 86
    Elżbieta Lorenc-Koci, Jacek Wójcikowski, Marta Kot, Anna Haduch, Jan Boksa, Władysława Anna Daniel, Disposition of 1,2,3,4,-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats, Brain Research, 2004, 996, 2, 168

    CrossRef

  87. 87
    Katherine R. Mickley, Dean E. Dluzen, Dose-Response Effects of Estrogen and Tamoxifen upon Methamphetamine-Induced Behavioral Responses and Neurotoxicity of the Nigrostriatal Dopaminergic System in Female Mice, Neuroendocrinology, 2004, 79, 6, 305

    CrossRef

  88. 88
    Taneli Heikkinen, Jukka Puoliväli, Heikki Tanila, Effects of long-term ovariectomy and estrogen treatment on maze learning in aged mice, Experimental Gerontology, 2004, 39, 9, 1277

    CrossRef

  89. 89
    JOANA GOMES-DA-SILVA, ROSARIO MIGUEL, JAVIER FERNÁNDEZ-RUIZ, TERESA SUMMAVIELLE, M AMÉLIA TAVARES, Effects of Neonatal Exposure to Methamphetamine: Catecholamine Levels in Brain Areas of the Developing Rat, Annals of the New York Academy of Sciences, 2004, 1025, 1
  90. 90
    Bin Liu, Jun Xia Xie, Dewi Kenneth Rowlands, Yu Lin Gou, Ching Cheong Leung, Yiu Wa Chung, Hsiao Chang Chan, Neuroprotective Effects of Bak Foong Pill in 1-Methyl-4-phenyl-1,2,3,6-tetrahyrdropyridine (MPTP)-Induced Parkinson's Disease Model Mice, Biological & Pharmaceutical Bulletin, 2004, 27, 8, 1245

    CrossRef

  91. 91
    Richard A. Lochhead, Ramin V. Parsey, Maria A. Oquendo, J.John Mann, Regional brain gray matter volume differences in patients with bipolar disorder as assessed by optimized voxel-based morphometry, Biological Psychiatry, 2004, 55, 12, 1154

    CrossRef

  92. 92
    Glenda E Gillies, Hilary E Murray, David Dexter, Simon McArthur, Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease, Pharmacology Biochemistry and Behavior, 2004, 78, 3, 513

    CrossRef

  93. 93
    Dean E. Dluzen, The effect of gender and the neurotrophin, BDNF, upon methamphetamine-induced neurotoxicity of the nigrostriatal dopaminergic system in mice, Neuroscience Letters, 2004, 359, 3, 135

    CrossRef

  94. 94
    James O’Callaghan, Krishnan Sriram, The Role of Glia in Neurotoxicity, Second Edition, 2004,

    CrossRef

  95. 95
    Annabell C. Segarra, Susan J. Lee, Principles of Gender-Specific Medicine, 2004,

    CrossRef

  96. 96
    Tiesong Shang, Alexander V. Uihlein, Jennifer Van Asten, Balaraman Kalyanaraman, Cecilia J. Hillard, 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3, Journal of Neurochemistry, 2003, 85, 2
  97. 97
    Yu-Min Kuo, Hsiang-Hua Chen, Chih-Chang Shieh, Kuo-Pin Chuang, Chianfang G. Cherng, Lung Yu, 4-Hydroxytamoxifen attenuates methamphetamine-induced nigrostriatal dopaminergic toxicity in intact and gonadetomized mice, Journal of Neurochemistry, 2003, 87, 6
  98. 98
    Demetrius M. Maraganore, Mariza de Andrade, Timothy G. Lesnick, Matthew J. Farrer, James H. Bower, John A. Hardy, Walter A. Rocca, Complex interactions in Parkinson's disease: A two-phased approach, Movement Disorders, 2003, 18, 6
  99. 99
    Myreille D'Astous, Marc Morissette, Bastien Tanguay, Sophie Callier, Thérèse Di Paolo, Dehydroepiandrosterone (DHEA) such as 17β-estradiol prevents MPTP-induced dopamine depletion in mice, Synapse, 2003, 47, 1
  100. 100
    H.E. Murray, A.V. Pillai, S.R. McArthur, N. Razvi, K.P. Datla, D.T. Dexter, G.E. Gillies, Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females, Neuroscience, 2003, 116, 1, 213

    CrossRef

  101. 101
    I.A Moroz, H Rajabi, D Rodaros, J Stewart, Effects of sex and hormonal status on astrocytic basic fibroblast growth factor-2 and tyrosine hydroxylase immunoreactivity after medial forebrain bundle 6-hydroxydopamine lesions of the midbrain dopamine neurons, Neuroscience, 2003, 118, 2, 463

    CrossRef

  102. 102
    M.J Decker, G.E Hue, W.M Caudle, G.W Miller, G.L Keating, D.B Rye, Episodic neonatal hypoxia evokes executive dysfunction and regionally specific alterations in markers of dopamine signaling, Neuroscience, 2003, 117, 2, 417

    CrossRef

  103. 103
    Aristea S Galanopoulou, Elizabeth Medina Alm, Jana Velı́šková, Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats, Neuroscience Letters, 2003, 342, 3, 201

    CrossRef

  104. 104
    R.E. Myers, L.I. Anderson, D.E. Dluzen, Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice, Neuropharmacology, 2003, 44, 5, 624

    CrossRef

  105. 105
    M. Baldereschi, A. Di Carlo, P. Vanni, A. Ghetti, P. Carbonin, L. Amaducci, D. Inzitari, Lifestyle-related risk factors for Parkinson's disease: a population-based study, Acta Neurologica Scandinavica, 2003, 108, 4
  106. 106
    Cynthia A. Crawford, Michael T. Williams, Eva R. Newman, Sanders A. McDougall, Charles V. Vorhees, Methamphetamine exposure during the preweanling period causes prolonged changes in dorsal striatal protein kinase A activity, dopamine D2-like binding sites, and dopamine content, Synapse, 2003, 48, 3
  107. 107
    Michael Colla, Gabriele Ende, Markus Bohrer, Michael Deuschle, Golo Kronenberg, Fritz Henn, Isabella Heuser, MR spectroscopy in Alzheimer’s disease: gender differences in probabilistic learning capacity, Neurobiology of Aging, 2003, 24, 4, 545

    CrossRef

  108. 108
    Teresa Ravizza, Linda K Friedman, Solomon L Moshé, Jana Velı́šková, Sex differences in GABAAergic system in rat substantia nigra pars reticulata, International Journal of Developmental Neuroscience, 2003, 21, 5, 245

    CrossRef

  109. 109
    S.P. González, J.L. Lanchares, Terapia hormonal sustitutiva en pacientes con patología asociada, Progresos de Obstetricia y Ginecología, 2003, 46, 10, 455

    CrossRef

  110. 110
    Bernd Moosmann, Christian Behl, Antioxidants as treatment for neurodegenerative disorders, Expert Opinion on Investigational Drugs, 2002, 11, 10, 1407

    CrossRef

  111. 111
    M Tomas-Camardiel, M.C Sanchez-Hidalgo, M.J Sanchez del Pino, A Navarro, A Machado, J Cano, Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17β-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum, Neuroscience, 2002, 109, 3, 569

    CrossRef

  112. 112
    DEAN E. DLUZEN, JANET L. McDERMOTT, Estrogen, Anti-Estrogen, and Gender, Annals of the New York Academy of Sciences, 2002, 965, 1
  113. 113
    A. Ekue, J.-F. Boulanger, M. Morissette, T. Di Paolo, Lack of Effect of Testosterone and Dihydrotestosterone Compared to 17β-Oestradiol in 1-Methyl-4-Phenyl-1,2,3,6, Tetrahydropyridine-Mice, Journal of Neuroendocrinology, 2002, 14, 9
  114. 114
    Dean E Dluzen, Linda I Anderson, Charles F Pilati, Methamphetamine–gonadal steroid hormonal interactions:, Neurotoxicology and Teratology, 2002, 24, 2, 267

    CrossRef

  115. 115
    James O’Callaghan, A Roger Little, Site-Selective Neurotoxicity, 2002,

    CrossRef

  116. 116
    Esteban Muñoz, Pau Pastor, María José Martí, Francesc Valldeoriola, Eduardo Tolosa, Rafael Oliva, Enfermedad de Parkinson esporádica y familiar: estudio comparativo, Medicina Clínica, 2001, 116, 16, 601

    CrossRef

  117. 117
    Maria D. Benedetti, Demetrius M. Maraganore, James H. Bower, Shannon K. McDonnell, Brett J. Peterson, J. Eric Ahlskog, Daniel J. Schaid, Walter A. Rocca, Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study, Movement Disorders, 2001, 16, 5
  118. 118
    Luis Miguel Garcia-Segura, Iñigo Azcoitia, Lydia L. DonCarlos, Neuroprotection by estradiol, Progress in Neurobiology, 2001, 63, 1, 29

    CrossRef

  119. 119
    Jana Velíšková, Solomon L. Moshé, Sexual dimorphism and developmental regulation of substantia nigra function, Annals of Neurology, 2001, 50, 5
  120. 120
    X Gao, D.E Dluzen, Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system, Neuroscience, 2001, 103, 2, 385

    CrossRef

  121. 121
    D. E. Dluzen, J. L. McDermott, L. I. Anderson, Tamoxifen Diminishes Methamphetamine-Induced Striatal Dopamine Depletion in Intact Female and Male Mice, Journal of Neuroendocrinology, 2001, 13, 7
  122. 122
    Dean E. Dluzen, Janet L. Mcdermott, Linda I. Anderson, Tamoxifen eliminates estrogen’s neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system, Neurotoxicity Research, 2001, 3, 3, 291

    CrossRef

  123. 123
    Xuemei Gao, Dean E Dluzen, The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system, Brain Research, 2001, 892, 1, 63

    CrossRef

  124. 124
    Serge Przedborski, Vernice Jackson-Lewis, Ali B. Naini, Michael Jakowec, Giselle Petzinger, Reginald Miller, Muhammad Akram, The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety, Journal of Neurochemistry, 2001, 76, 5
  125. 125
    DIANE B. MILLER, JAMES P. O'CALLAGHAN, SYED F. ALI, Age as a Susceptibility Factor in the Striatal Dopaminergic Neurotoxicity Observed in the Mouse following Substituted Amphetamine Exposure, Annals of the New York Academy of Sciences, 2000, 914, 1
  126. 126
    Kimberly A Disshon, Dean E Dluzen, Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats, Brain Research, 2000, 868, 1, 95

    CrossRef

  127. 127
    José Manuel Martínez Lage, Antonio Oliveros-Cid, Pablo Martínez-Lage, Estrógenos y enfermedad de Alzheimer: bases, promesas y realidades, Medicina Clínica, 2000, 114, 19, 747

    CrossRef

  128. 128
    JOANA GOMES-DA-SILVA, ALBERTO PÉREZ-ROSADO, ROSARIO DE MIGUEL, JAVIER FERNÁNDEZ-RUIZ, M. CAROLINA SILVA, M. AMÉLIA TAVARES, Neonatal Methamphetamine in the Rat: Evidence for Gender-specific Differences upon Tyrosine Hydroxylase Enzyme in the Dopaminergic Nigrostriatal System, Annals of the New York Academy of Sciences, 2000, 914, 1
  129. 129
    DEAN E. DLUZEN, JANET L. McDERMOTT, Neuroprotective Role of Estrogen upon Methamphetamine and Related Neurotoxins within the Nigrostriatal Dopaminergic System, Annals of the New York Academy of Sciences, 2000, 914, 1
  130. 130
    Sophie Callier, Marc Morissette, Michelle Grbois, Thérèse Di Paolo, Stereospecific prevention by 17β-estradiol of MPTP-induced dopamine depletion in mice, Synapse, 2000, 37, 4
  131. 131
    Q.D. Walker, M.B. Rooney, R.M. Wightman, C.M. Kuhn, Dopamine release and uptake are greater in female than male rat striatum as measured by fast cyclic voltammetry, Neuroscience, 1999, 95, 4, 1061

    CrossRef

  132. 132
    Iñigo Azcoitia, Amanda Sierra, Luis Miguel Garcia-Segura, Localization of estrogen receptor β-immunoreactivity in astrocytes of the adult rat brain, Glia, 1999, 26, 3
  133. 133
    Graham Pawelec, Anti-Aging Medicine LiteratureWatch, Journal of Anti-Aging Medicine, 1998, 1, 3, 275

    CrossRef

  134. 134
    Naomi P. Visanji, Jonathan M. Brotchie, MPTP-Induced Models of Parkinson's Disease in Mice and Non-Human Primates, Current Protocols in Pharmacology,